Enhancement of insulin-like growth factor signaling in human breast cancer: Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo

Molecular Endocrinology

Volumn 13, Issue 5, 1999, Pages 787-796

  Lee, A V ^a   Jackson, J G ^a   Gooch, J L ^a   Hilsenbeck, S G ^a   Coronado Heinsohn, E ^a   Osborne, C K ^a   Yee, D ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RECURRENCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 0033305004     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.13.5.0274     Document Type: Article

References (56)

1. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
2. Growth regulation of human breast carcinoma occurs through regulated growth factor secretion
3. Insulin-like growth factors and breast cancer
4. Insulin-like growth factor receptors and binding proteins
5. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumor-igenicity
6. Prognostic significance of insulin-like growth factor-binding protein expression in axillary lymph node-negative breast cancer
7. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival
8. Type 1 IGF receptor in human breast diseases
9. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice
10. Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice
11. Reduced growth of human breast cancer xenografts in hosts homozygous for the lit mutation
12. Tamoxifen reduces serum insulin-like growth factor I (IGF-I)
13. Role of insulin-like growth factors and the type 1 insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells
14. Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780
15. Estradiol down-regulates the mannose-6-phosphate/insulin-like growth factor-II receptor gene and induces cathepsin-D in breast cancer cells: A receptor saturation mechanism to increase the secretion of lysosomal proenzymes
16. Insulin-like growth factor II mRNA expression in human breast cancer
17. Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: Use of IGFBP-1 as an inhibitor of insulin-like growth factor action
18. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells
19. Transforming potential of the insulin receptor substrate 1
20. Insulin-like growth factor-II over expression in MCF-7 cells induces phenotypic chances associated with malignant progression
21. Autocrine production of insulin like growth factor-II using an inducible expression system results in reduced estrogen sensitivity of MCF-7 human breast cancer cells
22. Paradoxical effects of overexpression of the type I insulin-like growth factor (IGF) receptor on the responsiveness of human breast cancer cells to IGFs and estradiol
23. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells
24. Differential roles of IRS-1 and SHC signaling pathways in breast cancer cells
25. Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol
26. Insulin receptor substrate-1 (IRS-1) is the predominant signaling molecule activated by insulin-like growth factor-I (IGF-I), insulin, and interleukin-4 (IL-4) in estrogen receptor-positive human breast cancer cells
27. Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma
28. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2
29. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution
30. 17β-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells
31. Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells
32. Extinction of insulin-like growth factor-1 mitogenic signaling by antiestrogen-stimulated fas-associated protein tyrosine phosphatase-1 in human breast cancer cells
33. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth-hormone-induced IGF-I messenger ribonucleic acid
34. Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus
35. Overexpression of IRS-1 in the human breast cancer cell line MCF-7 induces loss of estrogen requirements for growth and transformation
36. A restriction point for control of normal animal cell proliferation
37. Autocrine secretion and malignant transformation of cells
38. Insulin-like growth factor-II (IGF-II): A potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor
39. Mechanism of estrogen activation of c-myc oncogene expression
40. Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis
41. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle
42. A far upstream estrogen response element of the ovalbumin gene contains several half-palindromic 5'-TGACC-3' motifs acting synergistically
43. Characterization and regulation of the mouse insulin receptor substrate gene promoter
44. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer
45. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells
46. The IRS-signalling system during insulin and cytokine action
47. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells
48. Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: Interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen
49. The unliganded estrogen receptor (ER) transduces growth factor signals
50. Cross-coupling between insulin and estrogen receptor in human neuroblastoma cells
51. Biological differences among MCF-7 human breast cancer cell lines from different laboratories
52. 36B4 cDNA Used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO
53. Identification of an alternate type I insulin-like growth factor receptor beta subunit mRNA transcript
54. Nonparametric estimation from incomplete observations
55. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer